CN108627576A - The quantitative analysis method of Tadalafei in a kind of human plasma - Google Patents
The quantitative analysis method of Tadalafei in a kind of human plasma Download PDFInfo
- Publication number
- CN108627576A CN108627576A CN201710159580.2A CN201710159580A CN108627576A CN 108627576 A CN108627576 A CN 108627576A CN 201710159580 A CN201710159580 A CN 201710159580A CN 108627576 A CN108627576 A CN 108627576A
- Authority
- CN
- China
- Prior art keywords
- tadalafei
- solution
- concentration
- human plasma
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000004445 quantitative analysis Methods 0.000 title claims abstract description 26
- 239000012224 working solution Substances 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 238000012360 testing method Methods 0.000 claims abstract description 18
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 238000010828 elution Methods 0.000 claims abstract description 6
- 238000011088 calibration curve Methods 0.000 claims abstract description 3
- 238000012545 processing Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 64
- 239000000523 sample Substances 0.000 claims description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- 239000013062 quality control Sample Substances 0.000 claims description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 19
- 238000004458 analytical method Methods 0.000 claims description 18
- 150000002500 ions Chemical class 0.000 claims description 14
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 238000003860 storage Methods 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- BUTPBERGMJVRBM-UHFFFAOYSA-N methanol;methylsulfinylmethane Chemical compound OC.CS(C)=O BUTPBERGMJVRBM-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical class [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 238000005070 sampling Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 101100348341 Caenorhabditis elegans gas-1 gene Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 101100447658 Mus musculus Gas1 gene Proteins 0.000 claims description 3
- 238000000889 atomisation Methods 0.000 claims description 3
- 238000013480 data collection Methods 0.000 claims description 3
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000002000 scavenging effect Effects 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 abstract description 3
- 239000006166 lysate Substances 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract description 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 238000004885 tandem mass spectrometry Methods 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 27
- 239000007789 gas Substances 0.000 description 9
- 239000012491 analyte Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- -1 polypropylene Polymers 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical group C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention discloses a kind of quantitative analysis methods of Tadalafei in human plasma, include the following steps：（1）The preparation of standard working solution；（2）Sample treatment；（3）Standard curve making；（4）Quantitative analysis：By test specimen according to step（3）Method processing, and press step（3）The calibration curve equation of gained calculates, and obtains the concentration of Tadalafei in test specimen.Present invention application LC-MS technology (HPLC MS/MS) measures the concentration of Tadalafei in human plasma, the concentration of Tadalafei in accurate quantitative analysis human plasma, pass through the reasonable selection of chromatographic column, lysate, mobile phase, Mass Spectrometry Conditions etc., the optimization of the process conditions such as flow velocity, type of elution, Mass Spectrometry Conditions, easy to operate, repeatability is high, and accuracy is good, operability is strong, can directly apply to sample detection in bioequivalence and analyze.
Description
Technical field
The invention belongs to field of bioanalysis, more particularly, to a kind of application LC-MS technology (HPLC-MS/MS)
Quantitative analysis method to Tadalafei in human plasma.
Background technology
It is estimated that 1.5 hundred million erectile dysfunction (ED) patient is had more than in worldwide, with population in the world old-age group
Change, the quantity of ED patient will also constantly rise.Tadalafil tablet is cyclic guanosine monophosphate (cGMP) specific phosphodiesterase enzyme 5
(PDE5) selective reversible inhibitor, when sexual stimulus causes part to discharge nitric oxide, PDE5 is inhibited by Tadalafei, makes
CGMP levels improve in penis sponge body, this causes smooth muscle relaxation, blood to flow into penile tissue, generate erection, such as asexual thorn
Swash.In the end of the year 2013, gift is come in the Chinese Xi Aili (Tadalafei) for being proposed 5mg low dose peroral dosage forms once a day, phase
Same curative effect, the one third of price only viagra (Xi Dila is non-).The powerful demand in Chinese imitation medicine market, not only cheap but also effect
The pretty good drug demand of quality can reduce the financial burden.It develops the biological detecting method of Tadalafei and is applied to Tadalafei
Imitation medicine Conformance Assessment have broad prospects.
In imitation medicine Conformance Assessment, more preferable more stable carry out evaluation of bioequivalence, the detection of drug how are determined
Analysis seems extremely important.Complicated component, the Matrix effects of Tadalafei biological sample are big, while the more difficult acquisition of sample and amount
Few, the concentration of analyte is usually very low, therefore higher and higher to biological sample separate analytical technique requirement, and there is an urgent need for build
A kind of vertical highly sensitive, highly selective Tadalafei content analysis method.
Invention content
The present invention for the above-mentioned prior art in deficiency, set about in terms of sample pre-treatments and detection technique two, provide
The quantitative analysis method of Tadalafei in a kind of human plasma.
The above-mentioned purpose of the present invention is achieved by the following technical programs.
The quantitative analysis method of Tadalafei, includes the following steps in a kind of human plasma：
(1) preparation of standard working solution：Tadalafei is weighed, volume ratio 9 is added:1 methanol-dimethylsulfoxide solution is matched
A concentration of 0.100~5.000mgmL is made-1Tadalafei storing solution, by the Tadalafei storing solution volume ratio 1:1
Methanol aqueous solution be diluted to gradient concentration be 40.0~40000ngmL-1Tadalafei working solution；By above-mentioned steps weight
Multiple primary, it is 40.0~320000ngmL to be configured to gradient concentration-1Tadalafei multiple operation solution；Weigh Ta Dala
Volume ratio 9 is added in non-d3:1 methanol-dimethylsulfoxide solution is configured to a concentration of 0.050~2.000mgmL-1Internal standard storage
Standby liquid, with volume ratio 1:1 methanol aqueous solution is diluted to 300~500ngmL-1Internal standard working solution；All storing solutions and
Working solution preserves at 0~10 DEG C, spare；
Blank people's normal plasma is taken, the Tadalafei working solution is separately added into, mixing is configured to the school of corresponding gradient
Positive standard specimen, concentration range are 2.00~2000ngmL-1；Blank people's normal plasma is taken, it is flat to be separately added into the Tadalafei
Row working solution, mixing are configured to the quality-control sample of corresponding gradient, gradient concentration ranging from 2.00~16000ngmL-1；
(2) sample treatment：Isometric the proofreaded sample, quality-control sample, test specimen, blank human plasma and water are taken, toward school
It is separately added into isometric internal standard working solution in positive standard specimen, quality-control sample, test specimen, toward blank human plasma and moisture
Isometric methanol aqueous solution is not added；Acetonitrile, mixing, centrifugation, transfer supernatant to first are added into above-mentioned each mixed liquor
In alcohol solution, mixing preserves each extract；
(3) standard curve making：Step (2) is obtained into the proofreaded sample, the extract of quality-control sample carries out LC-MS/MS points
Analysis measure, using the chromatographic peak area of Tadalafei and internal standard Tadalafei ratio as ordinate, in human plasma Tadalafei it is dense
Degree is that abscissa makes standard curve；
(4) quantitative analysis：Test specimen is handled according to the method for step (3), and by the standard curve obtained by step (3)
Equation calculation obtains the concentration of Tadalafei in test specimen.
The structural formula of Tadalafei is as follows：
Preferably, the operating condition of the analyses of LC-MS/MS described in step (3) continuous mode is：
A. chromatographic condition：Chromatographic column is UItimateXB C18；Mobile phase A：Water containing 0.1% formic acid and 10mM ammonium formates
Solution；Mobile phase B：Acetonitrile；Column oven temperature：30℃；Flow velocity：1.0mL/min；Column pressure when chromatographic column equilibrium state：11.5
~12.5MPa；Type of elution is gradient elution；
B. Mass Spectrometry Conditions：Ion source is the sources ESI, using positive ion mode, multiple-reaction monitoring pattern；Electron spray voltage：
4500V；Vortex ionspray temperature：650℃；Gas curtain gas type：30psi；Collision cell gas：Middle rank；Atomization gas type Gas1：
50psi；Assist gas Gas 2：60psi；Data collection time：3min.
Preferably, a concentration of 1.00mgmL of Tadalafei storing solution described in step (1)-1, the internal standard storing solution
A concentration of 0.500mgmL-1, the gradient concentration of the Tadalafei working solution is respectively 40.0,80.0,400,1600,
4000、20000、36000、40000ng·mL-1, the concentration gradient of the Tadalafei multiple operation solution is 40.0,120,
1800、30000、320000ng·mL-1, a concentration of 400ngmL of the internal standard working solution-1。
Preferably, the gradient concentration of step (1) described quality-control sample be respectively 2.00,6.00,90.0,1500,
16000ng·mL-1, the quality-control sample is in -15~-90 DEG C of storages；The gradient concentration of the proofreaded sample is respectively 2.00,
4.00、20.0、80.0、200、1000、1800、2000ng·mL-1, the proofreaded sample is Fresh.
Preferably, the condition of step (2) described centrifugation is to centrifuge 15min with the speed of 1700 × g.
Preferably, it is 9 that step (1) is also separately added into volume ratio into the Tadalafei storing solution, internal standard working solution:
1 methanol-dimethylsulfoxide solution is diluted, and preparation obtains accuracy/estimation of stability solution.
Preferably, step (3) described chromatographic condition further includes：5.00 μ L of sampling volume；Autosampler cleaning solution is
Methanol；Autosampler washes needle body product：200μL；Pressure foot lifting amount：50mm；Soaking time 2s when automatic sampling needle cleans；Automatically
Injector cleaning model：It is cleaned after cleaning and sample introduction before sample introduction；Autosampler temperature：4.0℃；When autosampler cleans
Between：1s.
Preferably, step (3) described Mass Spectrometry Conditions further include：Entrance potential 10V, collision cell exit potential 15V.
Preferably, the monitoring ion pair of Tadalafei is 390.2/ in step (3) the LC-MS/MS analyses continuous mode
268, internal standard Tadalafei-d3Monitoring ion pair be 393.2/271；One ion pair when institute residence time of scanning every time
150ms removes cluster voltage 90V, collision energy 17.00eV, retention time 1.27min.
The prior art is compared, and advantageous effect of the present invention is：(1) extraction recovery is improved, substantially all 70% or more.
(2) reduce matrix effect, absolute matrix factors have reached between 0.85~1.15.(3) selectivity is enhanced, is reduced to analysis
The interference of object and uantitative analytical.(4) detection sensitivity is improved, it is determined that quantification range so that expected lower limit of quantitation
Sample meets quantitative analysis requirement.Present invention application LC-MS technology (HPLC-MS/MS) measures Tadalafei in human plasma
Concentration, the concentration of Tadalafei, passes through the reasonable of chromatographic column, lysate, mobile phase, Mass Spectrometry Conditions etc. in accurate quantitative analysis human plasma
Selection, the optimization of the process conditions such as flow velocity, type of elution, Mass Spectrometry Conditions so that the quantitative detecting method of Tadalafei of the present invention
Practical, easy to operate, automation equipment degree is high, and repeatability is high, and accuracy is good, and operability is strong, can directly use
Sample detection is analyzed in bioequivalence.
Description of the drawings
Fig. 1 is the standard curve of the quantitative analysis method of Tadalafei in the present inventor's blood plasma.
Specific implementation mode
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.Unless stated otherwise, the present invention uses reagent, method and apparatus is the art conventional reagent, methods
And equipment.
The quantitative analysis method of Tadalafei, includes the following steps in the human plasma that the present invention establishes：
(1) preparation of standard working solution：Tadalafei is weighed, volume ratio 9 is added:1 methanol-dimethylsulfoxide solution is matched
A concentration of 0.100~5.000mgmL is made-1Tadalafei storing solution, by the Tadalafei storing solution volume ratio 1:1
Methanol aqueous solution be diluted to gradient concentration be 40.0~40000ngmL-1Tadalafei working solution；By above-mentioned steps weight
Multiple primary, it is 40.0~320000ngmL to be configured to gradient concentration-1Tadalafei multiple operation solution；Weigh Ta Dala
Volume ratio 9 is added in non-d3:1 methanol-dimethylsulfoxide solution is configured to a concentration of 0.050~2.000mgmL-1Internal standard storage
Standby liquid, with volume ratio 1:1 methanol aqueous solution is diluted to 300~500ngmL-1Internal standard working solution；All storing solutions and
Working solution preserves at 0~10 DEG C, spare；
Blank people's normal plasma is taken, the Tadalafei working solution is separately added into, mixing is configured to the school of corresponding gradient
Positive standard specimen, concentration range are 2.00~2000ngmL-1；Blank people's normal plasma is taken, it is flat to be separately added into the Tadalafei
Row working solution, mixing are configured to the quality-control sample of corresponding gradient, gradient concentration ranging from 2.00~16000ngmL-1；
(2) sample treatment：Isometric the proofreaded sample, quality-control sample, test specimen, blank human plasma and water are taken, toward school
It is separately added into isometric internal standard working solution in positive standard specimen, quality-control sample, test specimen, toward blank human plasma and moisture
Isometric methanol aqueous solution is not added；Acetonitrile, mixing, centrifugation, transfer supernatant to first are added into above-mentioned each mixed liquor
In alcohol solution, mixing preserves each extract；
(3) standard curve making：Step (2) is obtained into the proofreaded sample, the extract of quality-control sample carries out LC-MS/MS points
Analysis measure, using the chromatographic peak area of Tadalafei and internal standard Tadalafei ratio as ordinate, in human plasma Tadalafei it is dense
Degree is that abscissa makes standard curve；
(4) quantitative analysis：Test specimen is handled according to the method for step (3), and by the standard curve obtained by step (3)
Equation calculation obtains the concentration of Tadalafei in test specimen.
The method of the present invention is further described by taking specific implementation condition as an example below.
The preparation of embodiment 1 experimental solutions and working solution
Mobile phase A [is denoted as MPA]：1.00mL formic acid and about 631mg are added in the vial equipped with 1000mL ultra-pure waters
Ammonium formate vibrates mixing, the aqueous solution containing 0.1% formic acid and 10mM ammonium formates is made.Condition of storage：Room temperature.The term of validity：2 weeks.
Mobile phase B [is denoted as MPB]：1.00mL formic acid is added in the vial equipped with 1000mL acetonitriles, vibrates mixing, system
At chromatographic grade acetonitrile solution.Condition of storage：Room temperature.The term of validity：2 weeks.
Methanol：Water (50:50, v:V) [it is denoted as R01]：500mL methanol and 500mL water, oscillation are added in a vial
Mixing.Condition of storage：Room temperature.The term of validity：1 month.
Methanol：Dimethyl sulfoxide (9:1, v:V) [it is denoted as R02]：18.0mL methanol and 2.00mL are added in a vial
Dimethyl sulfoxide vibrates mixing.Condition of storage：Room temperature.The term of validity：3 months.
The storing solution of Tadalafei is weighed by independent twice, prepares obtain respectively.The storing solution of all preparations should all be protected
There are in 0~10 DEG C of refrigerator.The term of validity is set as 1 year, but its stability can be evaluated in 1 year, with the practical steady of measurement
Subject to qualitative data.The working solution for preparing the proofreaded sample and quality-control sample must be from the storing solution independently weighed twice.
Tadalafei storing solution [is denoted as S01], 1.00mg/mL：A certain amount of Tadalafei is weighed respectively and is positioned over two
In a vial, weight is recorded, S01-1, S01-2 are respectively labeled as.According to the purity of Tadalafei, moisture, whether at salt and
The information such as its form calculate the actual weight of the analyte, are added suitable R02, with ultimate density is 1.00mg/mL's
Tadalafei storing solution, vortex mixed；It when necessary can the dissolving of ultrasonic wave added compound.
Internal standard storing solution [is denoted as I01], 0.500mg/mL：Weigh a certain amount of Tadalafei-d3In vial, record
Weight is labeled as I01.According to Tadalafei-d3Purity, moisture, whether really weighed at salt and its form calculus interior target
Amount.Suitable R02 is added, with ultimate density be 0.500mg/mL Tadalafei-d3 internal standard storing solutions, vortex mixed；It must
It can the dissolving of ultrasonic wave added compound when wanting.
Internal standard working solution (400ng/mL) [being denoted as I02]：The R01 of 49.96mL is added in vial, then uses liquid relief
Tadalafei-the d of 40.0 μ L is added into bottle for device3Internal standard storing solution I01, vortex mixed.I02 is stored in 0~10 DEG C of refrigerator,
Validity date is two months.
The preparation of analyte working solution：In vial or polypropylene centrifuge tube, it is added such as specified volume in following table
R01, source solution, vortex mixed.The working solution of all preparations is all stored in 0~10 DEG C of refrigerator.Obtaining, work is molten
Before the extended storage stability data of liquid, the term of validity is set as two months.
Note：S01-1 is Tadalafei storing solution, is subsequently used for preparing the proofreaded sample；S01-2 is the parallel deposit of Tadalafei
Liquid is subsequently used for preparing quality-control sample；C01-C13 represents working solution.
The preparation of the proofreaded sample：In polypropylene centrifuge tube, as shown in following table, suitable blank people is added with pipettor
Normal plasma, adds corresponding source solution, and vortex mixing (about 30 seconds) is configured to corresponding the proofreaded sample.It is tested in method
In each analysis of card batch, the proofreaded sample all should Fresh.
Note：The dose volume of the proofreaded sample can adjust according to actual needs, but final aimed concn must keep one
It causes,
And it records faithfully.
The preparation of quality-control sample：In polypropylene centrifuge tube, as shown in following table, suitable blank people is added with pipettor
Then normal plasma adds corresponding source solution, vortex mixing (about 30 seconds) is configured to corresponding quality-control sample.In order to
Convenient for using and reducing number of freezing and thawing later, quality-control sample is divided into several equal portions.It is specific as follows：Transfer appropriate volume (it is recommended that
200 μ L) quality-control sample to the polypropylene cryopreservation tube that has marked in advance in, store for future use.The quality-control sample prepared is stored -15
In ice 1 at a temperature of~-35 DEG C or -60~-90 DEG C.
Note：The dose volume of quality-control sample can adjust according to actual needs, but final aimed concn must keep one
It causes, and correctly records.* QC-16000 is dilution QC (DQC) sample, for diluting 10 times of reliability evaluations.
The preparation of accuracy/estimation of stability solution：It is added into vial or polypropylene centrifuge tube as following table middle finger is fixed
Then suitable specified dilute solution is added in the source solution of volume, accuracy or the estimation of stability for making setting concentration are molten
Liquid, vortex mixed.Then by the solution storage in 0~10 DEG C of refrigerator, the term of validity is 1 week.Also can after Fresh immediately into
Row analysis test.
Note：The dose volume of solution can adjust according to actual needs, but final aimed concn must be consistent, and
It records faithfully.Weighing accuracy of the SC2 solution for two parts of storing solutions of the parallel preparation of analyte compares, it can also be used to analyte
The estimation of stability of storing solution.
Embodiment 2
The LC-MS/MS quantitative analysis methods of Tadalafei, include the following steps in a kind of human plasma：
(1) preparation of standard working solution：The gradient concentration of Tadalafei working solution is respectively 40.0,80.0,400,
1600、4000、20000、36000、40000ng·mL-1, the concentration gradient of Tadalafei multiple operation solution is 40.0,120,
1800、30000、320000ng·mL-1；The gradient concentration of the proofreaded sample is respectively 2.00,4.00,20.0,80.0,200,
1000、1800、2000ng·mL-1, the concentration of quality-control sample is respectively 2.00,6.00,90.0,1500,16000ng
mL-1；
Internal standard working solution is 400ngmL-1；Accuracy/estimation of stability solution D IS is 20.0ngmL-1, SC1 is
2000ng·mL-1, SC2 20.0ngmL-1；
As long as the preparation of above-mentioned solution ensures final concentration, preparation method can be based on the system of each solution in embodiment 1
Preparation Method or other methods.
(2) sample treatment：Using pipettor, the bare substrate that 25.0 μ L are separately added into one piece of 96 hole deep-well plates is (empty
White man's blood plasma), water, test specimen and step (1) obtained the proofreaded sample, quality-control sample, be denoted as respectively bare substrate group,
Blank reagent group, sample sets, correction group and Quality Control group；Using pipettor, it is separately added into toward bare substrate group, blank reagent group
The R01 of 25.0 μ L is separately added into the internal standard working solution I02 of 25.0 μ L into sample sets, correction group, Quality Control group；
Using pipettor, the acetonitrile of 400 μ L, vortex mixed 5min, with 1700 in 4 DEG C of centrifuges are added to each sample
The speed of × g centrifuges 15 minutes；In the supernatant to 96 orifice plates equipped with 950 μ L R01 for shifting 50.0 μ L using pipettor, whirlpool
Mixing is revolved, sample introduction is analyzed for preparation；Before sample introduction is analyzed, all extracts after sample treatment are stored in the temperature of autosampler
Under degree or in 0~10 DEG C of refrigerator.
(3) standard curve making：Correction group that step (2) is obtained, Quality Control group extract carry out following LC-MS/MS surveys
Setting analysis, each analysis batch prepares a standard curve being made of 8 concentration level the proofreaded samples, while utilizing quality-control sample
It is detected.
Chromatographic condition：
Chromatographic column：Ultimate XB C18,2.1 × 50.0mm, 5.0 μm, Welch；
Mobile phase A (MPA)：Aqueous solution containing 0.1% formic acid and 10mM ammonium formates；
Mobile phase B (MPB)：Acetonitrile；
Flow velocity：1.00mL/min；
Sampling volume：5.00μL；
Substantially column pressure when chromatographic column equilibrium state：12.0Mpa；
Autosampler cleaning solution：Methanol；
Autosampler washes needle body product：200μL；
Pressure foot lifting amount：50mm；
Soaking time when autosampler sample introduction needle is cleaned：2s；
Dynamic injector cleaning model：Before sample introduction and after sample introduction；
Autosampler cleaning setting：It first rushes and steeps afterwards；
Autosampler scavenging period：1s；
Autosampler temperature：4℃；
Column oven temperature：30℃.
Chromatography gradient：
Note：Single sample sample introduction is analyzed period (Cycle Time)：About 3.5 minutes (since a sample sample introductions
Time difference when next sample starts sample introduction).
Mass Spectrometry Conditions：
Ion source：ESI；
Ionization mode：Positive ion mode；
Detection pattern：Multiple-reaction monitoring；
Electron spray voltage：4500V；
Vortex ionspray temperature：650℃
Gas curtain gas type：30psi；
Collision cell gaseous species：Middle rank；
Atomization gas type (Gas1)：50psi；
Assist gas type (Gas 2)：60psi；
Entrance potential：10v；
Collision cell exit potential：15v；
Data collection time：3.00min.
* it notes：Residence time, referred to herein as when monitoring ion pair, every time scan an ion pair when stopped when
Between.
The proofreaded sample, quality-control sample are detected by above-mentioned chromatography and Mass Spectrometry Conditions, chromatogram acquisition and chromatographic peak product
Divide and handled by software Analyst 1.6.2 (AB Sciex), with the chromatographic peak face of Tadalafei and internal standard Tadalafei-d3
Product is than being ordinate, with a concentration of abscissa of Tadalafei in human plasma, with weighting (W=1/x2) least square method is with blood plasma
The concentration (X) of middle Tadalafei carries out linear regression with peak area ratio (Y), and the regression equation (Y=a+bX) of gained is standard
Curve, specially y=0.00414x+0.000686 (r=0.9994), concentration unit ng/mL, the results showed that, Tadalafei exists
It is linear good within the scope of 2.00~2000ng/mL.
(4) quantitative analysis：Tadalafei is extracted from human plasma by the processing mode of liquid-liquid extraction, after vortex centrifugal,
Supernatant progress nitrogen is blown into concentration, is redissolved after drying, then carries out LC-MS/MS liquid matter connection according to the condition in step (3)
With analysis；The volume of test specimen used is 50.0mL, and the plasma anticoagulant agent of sample treatment is EDTA-K2.Obtained by step (3)
Calibration curve equation calculate, obtain the concentration of Tadalafei in test specimen.
Embodiment 3
The present embodiment measures the accuracy of Tadalafei concentration, precision in human plasma to LC-MS/MS methods in embodiment 2
Degree is evaluated.Each portion of quality-control sample for taking above-mentioned tetra- concentration of QC-2, QC-6, QC-90, QC-1500 of 20.0 μ L, by above-mentioned
Method operates, in each sample replication 3 times of concentration 3 in 1 day, and respectively in not 3 analyses batch of METHOD FOR CONTINUOUS DETERMINATION on the same day, meter
Precision is calculated, the results are shown in table below：
| Analysis batch | Accuracy (%) | Precision (n=5) (%) |
| QC-2 | 96.9 | 4.1 |
| QC-6 | 104.5 | 4.3 |
| QC-90 | 101.8 | 3.9 |
| QC-1500 | 103.6 | 1.8 |
The content LC-MS/MS detection methods of Tadalafei, extraction recovery exist in the human plasma sample that the present invention establishes
75% or more；Reduce matrix effect, absolute matrix factors have reached between 0.85~1.15；Enhance selectivity, reduction pair
The interference of analyte and uantitative analytical；Efficient stable, sensitive is detected, operability is strong, for Tadalafei equivalence
Research has great importance, and can directly apply to sample detection in bioequivalence and analyze, in Tadalafei imitation medicine one
It has broad application prospects in the evaluation of cause property.
The implementation of the present invention described in detail above is still, specific thin during present invention is not limited to the embodiments described above
Section can carry out a variety of simple variants to technical scheme of the present invention within the scope of the technical concept of the present invention, these simple changes
Type all belongs to the scope of protection of the present invention.
Claims (9)
1. the quantitative analysis method of Tadalafei in a kind of human plasma, which is characterized in that include the following steps：
（1）The preparation of standard working solution：Tadalafei is weighed, volume ratio 9 is added:1 methanol-dimethylsulfoxide solution is configured to
A concentration of 0.100~5.000 mg mL-1Tadalafei storing solution, by the Tadalafei storing solution volume ratio 1:1 first
It is 40.0~40000 ng mL that alcohol solution, which is diluted to gradient concentration,-1Tadalafei working solution；One is repeated by above-mentioned steps
Secondary, it is 40.0 ~ 320000 ng mL to be configured to gradient concentration-1Tadalafei multiple operation solution；Tadalafei-d3 is weighed,
Volume ratio 9 is added:1 methanol-dimethylsulfoxide solution is configured to a concentration of 0.050~2.000 mg mL-1Internal standard storing solution,
With volume ratio 1:1 methanol aqueous solution is diluted to 300~500 ng mL-1Internal standard working solution；All storing solutions and work are molten
Liquid preserves at 0 ~ 10 DEG C, spare；
Blank people's normal plasma is taken, the Tadalafei working solution is separately added into, mixing is configured to the correcting mark of corresponding gradient
Sample, concentration range are 2.00 ~ 2000 ng mL-1；Blank people's normal plasma is taken, the Tadalafei multiple operation is separately added into
Solution, mixing are configured to the quality-control sample of corresponding gradient, gradient concentration ranging from 2.00 ~ 16000 ng mL-1；
（2）Sample treatment：Isometric the proofreaded sample, quality-control sample, test specimen, blank human plasma and water are taken, toward correcting mark
It is separately added into isometric internal standard working solution in sample, quality-control sample, test specimen, adds respectively toward blank human plasma and water
Enter isometric methanol aqueous solution；Acetonitrile, mixing, centrifugation, transfer supernatant to methanol-water are added into above-mentioned each mixed liquor
In solution, mixing preserves each extract；
（3）Standard curve making：By step（2）Obtain the proofreaded sample, the extract of quality-control sample carries out LC-MS/MS analyses and surveys
It is fixed, using the chromatographic peak area of Tadalafei and internal standard Tadalafei ratio as ordinate, in human plasma Tadalafei it is a concentration of
Abscissa makes standard curve；
（4）Quantitative analysis：By test specimen according to step（3）Method processing, and press step（3）The calibration curve equation of gained
It calculates, obtains the concentration of Tadalafei in test specimen.
2. the quantitative analysis method of Tadalafei in a kind of human plasma according to claim 1, which is characterized in that step
（3）Described in LC-MS/MS analysis continuous mode operating condition be：
A. chromatographic condition：Chromatographic column is UItimateXB C18；Mobile phase A：Aqueous solution containing 0.1% formic acid and 10mM ammonium formates；
Mobile phase B：Acetonitrile；Column oven temperature：30℃；Flow velocity：1.0 mL/min；Column pressure when chromatographic column equilibrium state：11.5~
12.5 MPa；Type of elution is gradient elution；
B. Mass Spectrometry Conditions：Ion source is the sources ESI, using positive ion mode, multiple-reaction monitoring pattern；Electron spray voltage：4500V；
Vortex ionspray temperature：650℃；Gas curtain gas type：30psi；Collision cell gas：Middle rank；Atomization gas type Gas1：50
psi；Assist gas Gas 2：60 psi；Data collection time：3min.
3. the quantitative analysis method of Tadalafei in a kind of human plasma according to claim 1, it is characterised in that：Step
（1）Described in Tadalafei storing solution a concentration of 1.00 mg mL-1, a concentration of 0.500 mg mL of the internal standard storing solution-1, the gradient concentration of the Tadalafei working solution is respectively 40.0,80.0,400,1600,4000,20000,36000,
40000 ng•mL-1, the concentration gradient of the Tadalafei multiple operation solution is 40.0,120,1800,30000,320000
ng•mL-1, a concentration of 400 ng mL of the internal standard working solution-1。
4. the quantitative analysis method of Tadalafei in a kind of human plasma according to claim 1, which is characterized in that step
（1）The gradient concentration of the quality-control sample is respectively 2.00,6.00,90.0,1500,16000 ng mL-1, the quality-control sample
In -15 ~ -90 DEG C of storages；The gradient concentration of the proofreaded sample is respectively 2.00,4.00,20.0,80.0,200,1000,
1800、2000 ng•mL-1, the proofreaded sample is Fresh.
5. the quantitative analysis method of Tadalafei in a kind of human plasma according to claim 1, which is characterized in that step
（2）The condition of the centrifugation is to centrifuge 15min with the speed of 1700 × g.
6. the quantitative analysis method of Tadalafei in a kind of human plasma according to claim 1, it is characterised in that：Step
（1）It is 9 that volume ratio is also separately added into the Tadalafei storing solution, internal standard working solution:1 methanol-dimethylsulfoxide is molten
Liquid is diluted, and preparation obtains accuracy/estimation of stability solution.
7. the quantitative analysis method of Tadalafei in a kind of human plasma according to claim 2, which is characterized in that step
（3）The chromatographic condition further includes：5.00 μ L of sampling volume；Autosampler cleaning solution is methanol；Autosampler washes needle
Volume：200 μL；Pressure foot lifting amount：50 mm；2 s of soaking time when automatic sampling needle cleans；Autosampler cleaning model：
It is cleaned after cleaning and sample introduction before sample introduction；Autosampler temperature：4.0℃；Autosampler scavenging period：1 s.
8. the quantitative analysis method of Tadalafei in a kind of human plasma according to claim 2, which is characterized in that step
（3）The Mass Spectrometry Conditions further include：10 V of entrance potential, collision cell exit potential 15V.
9. the quantitative analysis method of Tadalafei in a kind of human plasma according to claim 2, which is characterized in that step
（3）The monitoring ion pair of Tadalafei is 390.2/268 in the LC-MS/MS analyses continuous mode, internal standard Tadalafei-d3
Monitoring ion pair be 393.2/271；One 150 ms of ion pair when institute residence time of scanning every time, removes 90 V of cluster voltage,
17.00 eV of collision energy, 1.27 min of retention time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710159580.2A CN108627576A (en) | 2017-03-17 | 2017-03-17 | The quantitative analysis method of Tadalafei in a kind of human plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710159580.2A CN108627576A (en) | 2017-03-17 | 2017-03-17 | The quantitative analysis method of Tadalafei in a kind of human plasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108627576A true CN108627576A (en) | 2018-10-09 |
Family
ID=63686883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710159580.2A Pending CN108627576A (en) | 2017-03-17 | 2017-03-17 | The quantitative analysis method of Tadalafei in a kind of human plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108627576A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109541106A (en) * | 2018-11-30 | 2019-03-29 | 徐州佳生医药科技有限公司 | A kind of method that LC-MS measures frusemide concentration in blood plasma |
| CN109682912A (en) * | 2019-01-16 | 2019-04-26 | 徐州立兴佳正医药科技有限公司 | A kind of method that LC-MS measures celecoxib concentration in blood plasma |
| CN110927307A (en) * | 2019-11-07 | 2020-03-27 | 徐州立兴佳正医药科技有限公司 | Method for determining concentration of tadalafil in blood plasma by liquid chromatography-mass spectrometry |
| CN110940755A (en) * | 2019-12-18 | 2020-03-31 | 山西省食品药品检验所(山西省药品包装材料监测中心) | Method for detecting 4 tadalafil substances in food |
| CN111337597A (en) * | 2020-05-06 | 2020-06-26 | 苏州必宜生物科技有限公司 | Method for rapidly detecting concentration of tadalafil in blood plasma |
| CN112394122A (en) * | 2021-01-19 | 2021-02-23 | 潍坊市检验检测中心 | Method for detecting content of 3-hydroxypropyl demethyl tadalafil in health food |
| CN112986459A (en) * | 2021-04-15 | 2021-06-18 | 安徽万邦医药科技股份有限公司 | LC-MS/MS detection method for linezolid in human plasma |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006091975A1 (en) * | 2005-02-25 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Process of synthesizing tadalafil |
| CN101021482A (en) * | 2007-03-20 | 2007-08-22 | 北京市药品检验所 | Method for detecting Tadalafei and derivative thereof |
| WO2013122470A1 (en) * | 2012-02-17 | 2013-08-22 | Emotional Brain B.V. | Methods of differentiating hypoactive sexual desire disorder and/or female sexual arousal disorder |
| CN105158358A (en) * | 2015-08-18 | 2015-12-16 | 江苏出入境检验检疫局动植物与食品检测中心 | Method for detecting illegally-added 42 chemicals in Chinese patent medicines and health care products simultaneously |
| CN105651884A (en) * | 2015-12-31 | 2016-06-08 | 无限极（中国）有限公司 | Detection method for chemical substance capable of improving yang deficiency and/or relieving fatigue |
| CN105842350A (en) * | 2015-05-14 | 2016-08-10 | 湖北生物医药产业技术研究院有限公司 | Method for analysis of tadalafil synthetic intermediates by high performance liquid chromatography |
| US20170000793A1 (en) * | 2007-04-11 | 2017-01-05 | Biomarin Pharmaceutical Inc. | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
-
2017
- 2017-03-17 CN CN201710159580.2A patent/CN108627576A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006091975A1 (en) * | 2005-02-25 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Process of synthesizing tadalafil |
| CN101021482A (en) * | 2007-03-20 | 2007-08-22 | 北京市药品检验所 | Method for detecting Tadalafei and derivative thereof |
| US20170000793A1 (en) * | 2007-04-11 | 2017-01-05 | Biomarin Pharmaceutical Inc. | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| WO2013122470A1 (en) * | 2012-02-17 | 2013-08-22 | Emotional Brain B.V. | Methods of differentiating hypoactive sexual desire disorder and/or female sexual arousal disorder |
| CN105842350A (en) * | 2015-05-14 | 2016-08-10 | 湖北生物医药产业技术研究院有限公司 | Method for analysis of tadalafil synthetic intermediates by high performance liquid chromatography |
| CN105158358A (en) * | 2015-08-18 | 2015-12-16 | 江苏出入境检验检疫局动植物与食品检测中心 | Method for detecting illegally-added 42 chemicals in Chinese patent medicines and health care products simultaneously |
| CN105651884A (en) * | 2015-12-31 | 2016-06-08 | 无限极（中国）有限公司 | Detection method for chemical substance capable of improving yang deficiency and/or relieving fatigue |
Non-Patent Citations (3)
| Title |
|---|
| KIM, KWANG-YOUL 等: "Validated UPLC-MS/MS method for the determination of tadalafil in human plasma and its application to a pharmacokinetic study", 《TRANSLATIONAL AND CLINICAL PHARMACOLOGY》 * |
| 周颖等: "单剂量口服他达拉非在中国健康男性受试者的药代动力学和安全性", 《中国临床药理学杂志》 * |
| 陈安珍 等: "UPLC-MS/MS检测补肾壮阳类中成药及保健品中添加的化学药", 《中成药》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109541106A (en) * | 2018-11-30 | 2019-03-29 | 徐州佳生医药科技有限公司 | A kind of method that LC-MS measures frusemide concentration in blood plasma |
| CN109682912A (en) * | 2019-01-16 | 2019-04-26 | 徐州立兴佳正医药科技有限公司 | A kind of method that LC-MS measures celecoxib concentration in blood plasma |
| CN110927307A (en) * | 2019-11-07 | 2020-03-27 | 徐州立兴佳正医药科技有限公司 | Method for determining concentration of tadalafil in blood plasma by liquid chromatography-mass spectrometry |
| CN110940755A (en) * | 2019-12-18 | 2020-03-31 | 山西省食品药品检验所(山西省药品包装材料监测中心) | Method for detecting 4 tadalafil substances in food |
| CN111337597A (en) * | 2020-05-06 | 2020-06-26 | 苏州必宜生物科技有限公司 | Method for rapidly detecting concentration of tadalafil in blood plasma |
| CN112394122A (en) * | 2021-01-19 | 2021-02-23 | 潍坊市检验检测中心 | Method for detecting content of 3-hydroxypropyl demethyl tadalafil in health food |
| CN112986459A (en) * | 2021-04-15 | 2021-06-18 | 安徽万邦医药科技股份有限公司 | LC-MS/MS detection method for linezolid in human plasma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108627576A (en) | The quantitative analysis method of Tadalafei in a kind of human plasma | |
| Vitku et al. | Development and validation of LC–MS/MS method for quantification of bisphenol A and estrogens in human plasma and seminal fluid | |
| Rezk et al. | Quantification of sofosbuvir and ledipasvir in human plasma by UPLC–MS/MS method: Application to fasting and fed bioequivalence studies | |
| Li et al. | A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma | |
| CN109668979A (en) | Method that is a kind of while detecting 17 kinds of antipsychotics in blood sample | |
| Nugbienyo et al. | Automated sugaring-out liquid-liquid extraction based on flow system coupled with HPLC-UV for the determination of procainamide in urine | |
| CN110068644B (en) | Method for determining concentration of olanzapine in plasma by high performance liquid chromatography tandem mass spectrometry | |
| CN110554114B (en) | Method for analyzing oligomeric isomaltose and isomers thereof in yoghourt | |
| CN105954453A (en) | Kit for simultaneously quantifying and detecting niacin, nicotinamide and pantothenic acid | |
| Rezk et al. | A novel LC–ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma | |
| Sundell et al. | Simultaneous quantification of four first line antitubercular drugs and metabolites in human plasma by hydrophilic interaction chromatography and tandem mass spectrometry | |
| CN102944636B (en) | High-efficiency liquid chromatography to mass spectrum detection method for ethyl carbamate in distilled liquor | |
| Matta et al. | A validated liquid chromatography and tandem mass spectrometric method for simultaneous quantitation of tenofovir, emtricitabine, and efavirenz in human plasma and its pharmacokinetic application | |
| CN106908532B (en) | The method for measuring aquatic products Malachite Green, quinolones, sulfa drugs | |
| CN110031568B (en) | Method for determining concentration of Sacubitril, desethylSacubitril and valsartan in human plasma | |
| Liu et al. | Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry | |
| CN110927307A (en) | Method for determining concentration of tadalafil in blood plasma by liquid chromatography-mass spectrometry | |
| Said et al. | High performance liquid chromatography–Mass spectrometric bioanalytical method for the determination of dapoxetine in human plasma: Application for bioequivalence study | |
| CN108020627B (en) | Method for determining residual quantity of three phenoxy carboxylic acid pesticides in tobacco by ultra-high performance synthetic phase chromatography-tandem mass spectrometry | |
| CN110133169A (en) | A kind of method and application using frusemide in LC-MS detection human plasma | |
| CN111239303B (en) | Method for simultaneously determining concentrations of ticagrelor, active metabolites thereof and endogenous adenosine in human plasma by liquid chromatography-mass spectrometry | |
| CN106908543A (en) | The detection method of Gefitinib content in a kind of human plasma | |
| Wang et al. | Determination of anlotinib, a tyrosine kinase inhibitor, in rat plasma by UHPLC-MS/MS and its application to a pharmacokinetic study | |
| CN108627578A (en) | The quantitative analysis method of Simvastatin and Simvastatin hydroxyl acid concentration | |
| Pospíšilová et al. | Assay of acebutolol in pharmaceuticals by analytical capillary isotachophoresis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181009 |
|
| RJ01 | Rejection of invention patent application after publication |